🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
4.500
-0.260 (-5.46%)
At close: Nov 19, 2026, 4:00 PM EST
4.240
-0.260 (-5.78%)
After-hours: Nov 19, 2026, 7:59 PM EST

Cue Biopharma Statistics

Total Valuation

Cue Biopharma has a market cap or net worth of $32.69 million. The enterprise value is -$25.30 million.

Market Cap32.69M
Enterprise Value -25.30M

Important Dates

The last earnings date was Monday, November 16, 2026, after market close.

Earnings Date Nov 16, 2026
Ex-Dividend Date n/a

Share Statistics

Cue Biopharma has 7.26 million shares outstanding. The number of shares has increased by 120.66% in one year.

Current Share Class 7.26M
Shares Outstanding 7.26M
Shares Change (YoY) +120.66%
Shares Change (QoQ) +66.57%
Owned by Insiders (%) 7.34%
Owned by Institutions (%) 49.97%
Float 5.31M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.91
Forward PS 32.54
PB Ratio 0.96
P/TBV Ratio 0.85
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.38, with zero debt.

Current Ratio 3.38
Quick Ratio 3.20
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1,138.92

Financial Efficiency

Return on equity (ROE) is -800.39% and return on invested capital (ROIC) is -297.94%.

Return on Equity (ROE) -800.39%
Return on Assets (ROA) -417.95%
Return on Invested Capital (ROIC) -297.94%
Return on Capital Employed (ROCE) -289.95%
Weighted Average Cost of Capital (WACC) 19.73%
Revenue Per Employee $1.23M
Profits Per Employee -$7.13M
Employee Count29
Asset Turnover 0.72
Inventory Turnover n/a

Taxes

In the past 12 months, Cue Biopharma has paid $500,000 in taxes.

Income Tax 500,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -74.14% in the last 52 weeks. The beta is 2.81, so Cue Biopharma's price volatility has been higher than the market average.

Beta (5Y) 2.81
52-Week Price Change -74.14%
50-Day Moving Average 22.14
200-Day Moving Average 21.50
Relative Strength Index (RSI) 25.08
Average Volume (20 Days) 1,105,753

Short Selling Information

The latest short interest is 862,798, so 11.88% of the outstanding shares have been sold short.

Short Interest 862,798
Short Previous Month 792,553
Short % of Shares Out 11.88%
Short % of Float 16.25%
Short Ratio (days to cover) 5.12

Income Statement

In the last 12 months, Cue Biopharma had revenue of $35.64 million and -$206.68 million in losses. Loss per share was -$32.58.

Revenue35.64M
Gross Profit 19.81M
Operating Income -137.81M
Pretax Income -206.18M
Net Income -206.68M
EBITDA -136.50M
EBIT -137.81M
Loss Per Share -$32.58
Full Income Statement

Balance Sheet

The company has $57.99 million in cash and no debt, with a net cash position of $57.99 million or $7.98 per share.

Cash & Cash Equivalents 57.99M
Total Debt n/a
Net Cash 57.99M
Net Cash Per Share $7.98
Equity (Book Value) 38.40M
Book Value Per Share 4.95
Working Capital 46.98M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$51.10 million and capital expenditures -$121,000, giving a free cash flow of -$51.23 million.

Operating Cash Flow -51.10M
Capital Expenditures -121,000
Depreciation & Amortization 1.31M
Net Borrowing -1.50M
Free Cash Flow -51.23M
FCF Per Share -$7.05
Full Cash Flow Statement

Margins

Gross Margin 55.58%
Operating Margin -386.69%
Pretax Margin -578.53%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Cue Biopharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -120.66%
Shareholder Yield -120.66%
Earnings Yield -723.91%
FCF Yield -157.40%

Analyst Forecast

The average price target for Cue Biopharma is $68.67, which is 1,426.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target $68.67
Price Target Difference 1,426.00%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (3Y) -30.10%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on April 24, 2026. It was a reverse split with a ratio of 1:30.

Last Split Date Apr 24, 2026
Split Type Reverse
Split Ratio 1:30

Scores

Altman Z-Score n/a
Piotroski F-Score 4